543 related articles for article (PubMed ID: 23607863)
21. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency.
Favre O; Leimgruber A; Nicole A; Spertini F
Allergy; 2005 Mar; 60(3):385-90. PubMed ID: 15679727
[TBL] [Abstract][Full Text] [Related]
22. [Immunoglobulin substitution in patients with indolent non-Hodgkin's lymphoma].
Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
Dtsch Med Wochenschr; 2015 Sep; 140(19):e201-6. PubMed ID: 26402188
[TBL] [Abstract][Full Text] [Related]
23. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
24. [Intravenous immunoglobulins: anti-infection indications].
Mouthon L; Guillevin L
Ann Med Interne (Paris); 2000 Mar; 151(2):136-43. PubMed ID: 10855366
[TBL] [Abstract][Full Text] [Related]
25. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections.
Carbone J; Sarmiento E; Del Pozo N; Rodriguez-Molina JJ; Navarro J; Fernandez-Yañez J; Palomo J; Villa A; Muñoz P; Fernandez-Cruz E
Clin Transplant; 2012; 26(3):E277-83. PubMed ID: 22686951
[TBL] [Abstract][Full Text] [Related]
26. Safety monitoring of the intravenous immunoglobulin preparation Intratect® in primary and secondary immunodeficiencies: a prospective non-interventional study.
Bauhofer A; Dietrich RL; Schmeidl R
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):21-31. PubMed ID: 25345431
[TBL] [Abstract][Full Text] [Related]
27. Home self-administration of intravenous immunoglobulin therapy in children.
Kobayashi RH; Kobayashi AD; Lee N; Fischer S; Ochs HD
Pediatrics; 1990 May; 85(5):705-9. PubMed ID: 2109852
[TBL] [Abstract][Full Text] [Related]
28. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
Kallenberg CG
Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
[TBL] [Abstract][Full Text] [Related]
29. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
30. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
31. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
32. Role of gamma globulin.
Berger M; Gilbert I
Semin Respir Infect; 1989 Dec; 4(4):272-83. PubMed ID: 2516639
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma.
Schachter J; Katz U; Mahrer A; Barak D; David LZ; Nusbacher J; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():305-14. PubMed ID: 17911445
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
Ballow M
Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
37. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
[TBL] [Abstract][Full Text] [Related]
40. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
